Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CA-125

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    159 result(s) found for: CA-125. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2008-004438-25 Sponsor Protocol Number: 20060342 Start Date*: 2008-10-21
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
    Medical condition: Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cance
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002117-36 Sponsor Protocol Number: CT-CL02 Start Date*: 2018-11-28
    Sponsor Name:Cristal Therapeutics
    Full Title: A Phase IIa Exploratory Study of CriPec® docetaxel Monotherapy in Subjects with Platinum Resistant Ovarian Cancer.
    Medical condition: Platinum Resistant Ovarian Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008746-20 Sponsor Protocol Number: AGO 10 Start Date*: 2010-01-28
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: Randomized Phase II AGO-Study comparing combined liposomal doxorubicin (Myocet) and gemcitabine (Gemzar) with liposomal doxorubicin (Myocet) monotherapy in platinum-refractory and platinum-resistan...
    Medical condition: platinum-refractory and platinum-resistant epithelial cancer of the ovary, fallopian tube, and the peritoneum
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005960-68 Sponsor Protocol Number: D9319C00001 Start Date*: 2021-07-24
    Sponsor Name:Astrazeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioi...
    Medical condition: Olaparib Maintenance Monotherapy in Participants with BRCAWild Type Ovarian Cancer Following Response toFirst-line Platinum-based Chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000635-15 Sponsor Protocol Number: 307970 Start Date*: 2005-09-07
    Sponsor Name:Schering AG
    Full Title: Randomized, multicentre, prospective, two-arm, open-label Phase II study to investigate the efficacy and safety of two ZK219477 i.v. infusions (3-hour infusion of 16mg/m2 versus 0.5-hour infusion o...
    Medical condition: Recurrent ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000135-31 Sponsor Protocol Number: TABENETOC Start Date*: 2022-01-12
    Sponsor Name:Region Östergötland
    Full Title: The Effect of tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy – A randomized pilot study
    Medical condition: Epithelial ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002324-41 Sponsor Protocol Number: PH2/051 Start Date*: 2006-11-30
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplat...
    Medical condition: Progressive, advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003439-18 Sponsor Protocol Number: D0810C00019 Start Date*: 2009-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or mor...
    Medical condition: platinum sensitive serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) PL (Completed) CZ (Completed) ES (Completed) EE (Completed) FR (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004186-14 Sponsor Protocol Number: CORT125134-552 Start Date*: 2019-07-31
    Sponsor Name:Corcept Therapeutics Incorporated
    Full Title: A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Medical condition: Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004027-52 Sponsor Protocol Number: GINECO-OV125b Start Date*: 2015-11-30
    Sponsor Name:ARCAGY Research
    Full Title: Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB – IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer trea...
    Medical condition: Patients with advanced FIGO stage IIIB – IV high grade epithelial ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing) AT (Completed) BE (Completed) ES (Ongoing) DK (Completed) SE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011400-33 Sponsor Protocol Number: MO22224 Start Date*: 2009-08-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or...
    Medical condition: Platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed) NL (Completed) BE (Completed) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010319-34 Sponsor Protocol Number: OSI-906-202 Start Date*: 2009-09-24
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Phase 1/2 Study Evaluating Intermittent and Continuous OSI 906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
    Medical condition: Recurrent Epithelial Ovarian Cancer and Other Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019525-34 Sponsor Protocol Number: MO22923 Start Date*: 2010-12-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA
    Medical condition: EPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033128 Ovarian cancer LLT
    12.1 10052204 Ovarian carcinosarcoma LLT
    12.1 10016180 Fallopian tube cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Completed) FR (Completed) ES (Completed) LT (Completed) AT (Completed) LV (Completed) NL (Completed) IE (Completed) SE (Completed) EE (Completed) HU (Completed) IT (Completed) BG (Completed) DK (Completed) SI (Completed) GR (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003884-23 Sponsor Protocol Number: VB-111-701/GOG-3018 Start Date*: 2020-06-25
    Sponsor Name:Vascular Biogenics Ltd.
    Full Title: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Trea...
    Medical condition: Recurrent Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001472-10 Sponsor Protocol Number: INCB24360-210 Start Date*: 2012-10-19
    Sponsor Name:Incyte Corporation
    Full Title: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FAL...
    Medical condition: BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020030-25 Sponsor Protocol Number: APC-10E604 Start Date*: 2010-08-24
    Sponsor Name:ACCESS Pharmaceuticals, Inc
    Full Title: A Phase II Trial of ProLindac™ and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer
    Medical condition: Advanced Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001576-12 Sponsor Protocol Number: SGI-110-02 Start Date*: 2013-07-22
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer
    Medical condition: Platinum-Resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005744-17 Sponsor Protocol Number: ENDOMET-IA-DIULNG08 Start Date*: 2008-11-10
    Sponsor Name:PEDRO ACIEN ALVAREZ
    Full Title: INHIBIDORES DE LA AROMATASA (ANASTROZOL) ASOCIADOS A DISPOSITIVO INTRAUTERINO LIBERADOR DE LEVONORGESTREL (DIU-LNG) EN EL TRATAMIENTO DE LA ENDOMETRIOSIS MODERADA/SEVERA
    Medical condition: ENDOMETRIOSIS MODERADA/SEVERA
    Disease: Version SOC Term Classification Code Term Level
    9 10014778 Endometriosis LLT
    9 10014784 Endometriosis of ovary LLT
    9 10014788 Endometriosis related pain LLT
    9 10014785 Endometriosis of pelvic peritoneum LLT
    9 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007734-19 Sponsor Protocol Number: P53SLP01/01 Start Date*: 2008-07-03
    Sponsor Name:University Medical Center Groningen, UMCG-Department of Gynaecologic Oncology
    Full Title: p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer, a phase II trial.
    Medical condition: This is an uncontrolled, mono-centre, phase II single dose trial for patients with ovarian cancer, who have a rising serum tumor marker CA-125 after previous treatment (surgery and platinum based c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003066-39 Sponsor Protocol Number: 10UCS2018 Start Date*: 2022-02-21
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial. LEPRE Trial
    Medical condition: Patients with a low-grade serous epithelial carcinoma of the ovary (LGSCO) including cancer of fallopian tube and peritoneum, FIGO III-IV stage and with ER+ and/or PgR+ after primary surgery are el...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 10:48:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA